CervoMed Inc. 8-K

What Happened
CervoMed Inc. (CRVO) filed an 8-K on February 18, 2026, disclosing that its lead drug candidate, neflamapimod, has been selected for inclusion in EXPERTS-ALS, a platform trial funded by the U.K. National Institute for Health and Care Research (NIHR) and leading motor neuron disease charities that facilitates rapid testing of potential ALS treatments. The company issued a press release (attached as Exhibit 99.1 to the filing) and noted related presentation materials are available on its investor website.

Key Details

• Filing date: February 18, 2026 (Form 8-K, Items 7.01 and 8.01).
• Drug: neflamapimod — CervoMed’s lead drug candidate selected for the EXPERTS-ALS platform.
• Platform funders: U.K. NIHR and leading motor neuron disease charities; EXPERTS-ALS is designed to accelerate testing of ALS treatments.
• Disclosures: Press release attached as Exhibit 99.1; company presentation posted at www.cervomed.com under “Investors – Events and Presentations.”

Why It Matters
Inclusion in EXPERTS-ALS gives neflamapimod access to a coordinated, U.K.-backed platform for faster evaluation in ALS, which could advance CervoMed’s clinical development pathway and increase visibility with researchers and funders. The 8-K does not provide trial timelines, enrollment details, financial commitments, efficacy data, or changes to management or financial results — it primarily reports the selection and public disclosures (press release and presentation).